Search | Médecins Sans Frontières Access Campaign

71 results found

January 2020 protest in front of the New York Stock Exchange, demanding J&J make bedaquiline more accessible for all people with drug-resistant TB.

Press release |

30 September 2023

MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries

MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versions

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Press release |

19 September 2023

TB test price reduction by Cepheid and Danaher is an important step in the right direction

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert Johnson & Johnson

Bottle of bedaquiline, Zhytomyr Regional TB Dispensary, Ukraine. In 2018, MSF started providing treatment for drug-resistant TB to people in Zhytomyr, Ukraine.

Press release |

17 July 2023

MSF calls for commitment from pharma corporation J&J to not enforce extended patents on lifesaving TB drug as main patent expires in India, opening door to affordable generics

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson

Press release |

26 April 2023

MSF demands J&J give up its patent monopoly on TB drug to put lives over profits

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline Johnson & Johnson

MSF Doctor Joan providing a consultation to Nischaya, an XDR-TB patient, in the MSF clinic in Mumbai.

Press release |

23 March 2023

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend monopoly on lifesaving TB drug

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson India

Medical cooler box for the transportation of specimens (blood/sputum) from the point of specimen collection to the laboratory, used for the TB-PRACTECAL clinical trial. Clinical laboratory specimens must be transported at proper temperatures in order to preserve the viability and integrity of the specimen.

Press release |

22 December 2022

TB-PRACTECAL: Groundbreaking MSF trial finds better treatment for people with drug-resistant tuberculosis

Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...

Tags Tuberculosis drug-resistant TB TB AllianceJohnson & Johnson DRTB Drugs Under the Microscope

Issue brief |

16 December 2021

Liposomal amphotericin B: Solving the access puzzle

Liposomal amphotericin B is a lifesaving treatment for several diseases. Collaborative work among stakeholders is essential to overcome persistent access barriers.

Tags COVID-19HIV/AIDSTropical & neglected diseases mucormycosiscryptococcal meningitisvisceral leishmaniasis (kala azar) liposomal amphotericin B UNAIDS

MSF Counsellor, counselling parents of a six-year-old girl with drug-resistant TB at MSF independent Clinic, Mumbai- India

Press release |

03 September 2021

Lifesaving TB medicines must be affordable and available to make all-oral treatments for children a reality

The WHO recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. However paediatric ...

Tags Tuberculosis tuberculosis bedaquilinedelamanid World Health OrganizationJohnson & Johnson

Sebastião da Silva, 43 years old, is unemployed and went out of his house to get food for his 3 kids and wife. He is a painter and is having a hard time getting a job.If I get the virus, I wouldn’t know what to do.”

Press release |

26 July 2021

Opposing countries must stop filibustering negotiations on ‘TRIPS Waiver’ at WTO

Ahead of the WTO General Council meeting, MSF urged the EU, Norway, the UK, and Switzerland to stop stalling the landmark proposal to waive IP on lifesaving COVID-19 medical tools.

Tags COVID-19 coronavirus UNAIDSWorld Health OrganizationWTO covid medical tools access

Report |

13 May 2021

Ending cryptococcal meningitis deaths by 2030: Strategic framework

This Strategic Framework sets out the case for a re-invigorated global drive to end cryptococcal meningitis deaths by 2030, as part of a broader drive to end all HIV-related deaths, and outlines what essential programmatic elements are ...

Tags HIV/AIDS cryptococcal meningitis UNAIDSWorld Health Organization

MSF Nurse taking vitals of nine years old XDRTB + EPTB male child at MSF independent Clinic, Mumbai- India

Press release |

20 April 2021

MSF supports TB survivors’ court case for Indian government to override patents on lifesaving TB drugs

Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. MSF ...

Tags Tuberculosis drug-resistant TB bedaquilinedelamanid Johnson & JohnsonOtsuka

Press release |

25 February 2021

If approved, first shipments of J&J COVID-19 vaccine should go to low- and middle-income countries

Geneva, 25 February 2021 – The US Food and Drug Administration (FDA) will meet tomorrow to discuss emergency use authorisation of the Johnson & Johnson (J&J) COVID-19 vaccine candidate. If the vaccine is approved, Médecins Sans ...

Tags COVID-19 coronavirus Johnson & Johnson covid medical tools access

Bambari hospital, Central African Republic

Press release |

22 February 2021

MSF welcomes African Union’s motion supporting IP waiver proposal at WTO

MSF welcomes the endorsement by the AU that encourages all countries in Africa to support this landmark proposal at the WTO that would allow countries to choose not to apply or enforce certain types of IP on COVID-19 medical tools ...

Tags COVID-19 coronavirus DNDiUNAIDSWTO covid medical tools access

Alix Bommelear is an MSF doctor working in a mobile clinic in the north of Paris. She spends her days providing medical care to homeless people, most of whom are migrants or refugees who cannot access medical care elsewhere.

Press release |

29 January 2021

MSF response to release of Johnson & Johnson COVID-19 vaccine data

MSF urges J&J to prioritise initial supply of vaccine to COVAX, if approved

Tags COVID-19 coronavirus vaccines Johnson & Johnson covid medical tools access

covid 19 yemen patientbeingmoved jacobburns 2020

Press release |

11 November 2020

MSF: Governments must demand pharma make all COVID-19 vaccine licensing deals public

Terms of a deal disclosed show that we cannot rely on pharma’s goodwill to do the right thing, even in a pandemic.

Tags COVID-19 coronavirus vaccines Oxford UniversityAstraZenecaGlaxoSmithKlineJohnson & JohnsonPfizerSanofiSerum Institute of India covid medical tools access

Issue brief |

19 October 2020

DR-TB and TB-Prevention Drugs Under the Microscope, 7th Edition

Medicine pricing and patent issues for drug-resistant tuberculosis and tuberculosis prevention

Tags Tuberculosis drug-resistant TBtuberculosis pretomanidbedaquilinedelamanid Union Conference on Lung HealthJohnson & JohnsonOtsuka DRTB Drugs Under the Microscope

MSF protested in front of the New York Stock Exchange in New York on January 22, 2020, demanding the pharmaceutical corporation Johnson & Johnson (J&J) make the tuberculosis (TB) drug bedaquiline available for all people with drug-resistant TB (DR-TB) for no more than a dollar a day. The price of this crucial drug must be lowered to reflect the joint contributions made in the research and development of this drug by taxpayers, and the global scientific and TB community, including by MSF itself.

Press release |

06 July 2020

Johnson & Johnson TB drug price reduction is important step, and governments need to urgently scale up better treatment

The pharmaceutical corporation Johnson & Johnson (J&J) today announced a reduced price of US$1.50* per day for the tuberculosis (TB) drug bedaquiline, which is an important step that should allow more people with drug-resistant forms ...

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson

John * and Jean * hold each other’s arms in the CHK. Jean was diagnosed with HIV in 2010. He was hospitalized in June 2019 for the first time. A few weeks after his release, he had to return urgently for a new hospitalization.

Press release |

06 July 2020

MSF response to the release of UNAIDS 2020 Global AIDS Update Report

UNAIDS released today its 2020 Global AIDS Update Report. MSF joins UNAIDS in calling for countries to implement practices to help mitigate the impact of COVID-19 on HIV treatment services.

Tags HIV/AIDS coronavirusHIV/AIDS UNAIDS

MSF protests at Wall Street after J&J announces 2019 sales increase

Press release |

22 January 2020

As J&J release earnings, MSF protests price of lifesaving TB drug

MSF protested in front of the New York Stock Exchange in New York today, demanding the pharmaceutical corporation Johnson & Johnson make the tuberculosis drug bedaquiline available for all people with drug-resistant TB or no more than ...

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline access to medicines Johnson & Johnson

Report |

29 November 2019

No time to lose: detect, treat and prevent AIDS

AIDS related mortality remains high - 770,000 deaths in 2018 - and has hardly declined in recent years. This report, compiled by MSF, presents data from the AHD dashboard initiated by the HIV Advanced Disease Consortium (HIV-ADC).

Tags HIV/AIDS HIV/AIDS UNAIDS

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries

TB test price reduction by Cepheid and Danaher is an important step in the right direction

MSF calls for commitment from pharma corporation J&J to not enforce extended patents on lifesaving TB drug as main patent expires in India, opening door to affordable generics

MSF demands J&J give up its patent monopoly on TB drug to put lives over profits

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend monopoly on lifesaving TB drug

TB-PRACTECAL: Groundbreaking MSF trial finds better treatment for people with drug-resistant tuberculosis

Liposomal amphotericin B: Solving the access puzzle

Lifesaving TB medicines must be affordable and available to make all-oral treatments for children a reality

Opposing countries must stop filibustering negotiations on ‘TRIPS Waiver’ at WTO

Ending cryptococcal meningitis deaths by 2030: Strategic framework

MSF supports TB survivors’ court case for Indian government to override patents on lifesaving TB drugs

If approved, first shipments of J&J COVID-19 vaccine should go to low- and middle-income countries

MSF welcomes African Union’s motion supporting IP waiver proposal at WTO

MSF response to release of Johnson & Johnson COVID-19 vaccine data

MSF: Governments must demand pharma make all COVID-19 vaccine licensing deals public

DR-TB and TB-Prevention Drugs Under the Microscope, 7th Edition

Johnson & Johnson TB drug price reduction is important step, and governments need to urgently scale up better treatment

MSF response to the release of UNAIDS 2020 Global AIDS Update Report

As J&J release earnings, MSF protests price of lifesaving TB drug

No time to lose: detect, treat and prevent AIDS